Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.

Sabdia, Muhammed B; Patch, Ann-Marie; Tsang, Hennes; Gandhi, Maher K

Sabdia, Muhammed B; Patch, Ann-Marie; Tsang, Hennes; Gandhi, Maher K.

Affiliation

Sabdia MB; Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia. Electronic address: m.bilalsabdia@mater.uq.edu.au.
Patch AM; QIMR Berghofer Medical Research Institute, Herston, QLD, Australia. Electronic address: ann-marie.patch@qimrberghofer.edu.au.
Tsang H; Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia. Electronic address: hennes.tsang@uq.net.au.
Gandhi MK; Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia; Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia. Electronic address: maher.gandhi@mater.uq.edu.au.

Blood Rev ; 56: 100969, 2022 11.

Article de En | MEDLINE | ID: mdl-35570070

Sujet(s)
Mots clés

Antigen presentation; B-cell receptor; Immunoglobulin; Immunotherapy; Leukemia; Lymphoma; Lymphoproliferative disorders; Multiple myeloma; Neoantigen; Tumor specific antigen

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Syndromes lymphoprolifératifs / Tumeurs Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Blood Rev Sujet du journal: HEMATOLOGIA Année: 2022 Type de document: Article Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google